Hypothesis

In aged regenerative niches, increased extracellular matrix (ECM) stiffness activates integrin‑YAP/TAZ and RhoA signaling, which physically sequester Smoothened (SMO) from the primary cilium. This mislocalization reduces ciliary SMO accumulation, flattens the Sonic hedgehog (Shh)‑dependent GLI activator/repressor gradient, and biases GLI activity toward repressor forms. Consequently, SMO agonism fails to drive the pro‑angiogenic GLI1 program seen in young tissue and instead permits unchecked TGF‑β/Smad signaling, promoting fibrosis rather than repair.

Mechanistic Rationale

• ECM stiffening in aging engages integrin‑FAK‑Src cascades that activate YAP/TAZ nuclear translocation and RhoA‑ROCK‑mediated actin contractility [5].
• Both YAP/TAZ and heightened actin tension are known to interfere with intraflagellar transport and microtubule stability, processes required for ciliary entry of GPCRs such as SMO [5].
• When SMO is excluded from the cilium, Patched‑1 (PTCH1) inhibition is relieved at the membrane but not within the ciliary compartment, leading to low ciliary SMO despite agonist presence. This decouples ligand binding from downstream GLI processing.
• In young tissue, low ECM stiffness permits efficient SMO ciliary trafficking, producing a steep GLI2/GLI3 activator gradient that drives GLI1‑mediated angiogenesis and progenitor proliferation [1,2].
• In aged tissue, the resulting shallow GLI gradient favors GLI3 repressor formation, diminishing GLI1 transcription while allowing TGF‑β/Smad to dominate, a shift consistent with observed fibrotic outcomes in aged pressure ulcer models when Shh signaling is perturbed [1,6].
• Crosstalk prediction: YAP/TAZ or RhoA inhibition should restore ciliary SMO localization and steepen GLI gradients even in aged ECM, converting SMO agonist response from fibrotic to reparative.

Testable Predictions

1. Ciliary SMO Levels – Aged mouse skin or muscle injury models will show significantly lower SMO immunoreactivity within α‑tubulin‑positive primary cilia compared to young controls, both basally and after SAG treatment (quantified by immunofluorescence confocal microscopy).
2. GLI Gradient Shape – Using a GLI‑reporter mouse (e.g., Gli1‑lacZ or Gli‑GFP) combined with tissue clearing and light‑sheet microscopy, the spatial GLI activity profile across the wound edge will be shallow (low slope) in aged tissue and steep in young tissue; SAG will steepen the gradient only in young tissue.
3. Functional Rescue – Pharmacological inhibition of YAP/TAZ (verteporfin) or RhoA‑ROCK (Y‑27632) in aged injury models will increase ciliary SMO, restore a steep GLI gradient, enhance GLI1‑dependent angiogenesis (CD31+ vessel density), and reduce collagen deposition (Sirius Red) compared to vehicle.
4. Specificity – Manipulating Wnt or Notch pathways will not affect ciliary SMO localization under the same conditions, confirming the mechanospecific nature of the hypothesis.

Experimental Approach

• Models: Young (8‑week) and aged (18‑month) C57BL/6 mice subjected to full‑thickness excisional wounds or tibialis anterior muscle crush injury.
• Treatments: SAG (10 mg/kg, i.p.) ± verteporfin (50 mg/kg, i.p.) or Y‑27632 (10 mg/kg, i.p.) administered daily for 5 days post‑injury.
• Readouts: (a) Immunofluorescence for SMO and acetylated tubulin in cryosections; (b) GLI reporter activity via whole‑mount imaging and quantification of fluorescence intensity versus distance from wound edge; (c) Angiogenesis (CD31 immunostaining), fibrosis (collagen I/III, α‑SMA), and progenitor proliferation (Ki67+PDGFRα+).
• Analysis: Compare slope of GLI reporter gradient (linear regression) between groups; test interaction effects via two‑way ANOVA with age and treatment as factors.

If data show that aged tissue exhibits reduced ciliary SMO and flattened GLI gradients, and that mechanotransduction inhibition rescues both the gradient and reparative outcomes, the hypothesis will be supported. Conversely, if ciliary SMO levels and GLI gradients are unchanged with age or mechanostatic manipulation, the hypothesis will be falsified, directing attention toward alternative age‑dependent mechanisms (e.g., altered cholesterol availability or PTCH1 trafficking).